Dynasty Wealth Management LLC Takes Position in Takeda Pharmaceutical Co. $TAK

Dynasty Wealth Management LLC bought a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 48,220 shares of the company’s stock, valued at approximately $706,000.

A number of other large investors have also bought and sold shares of the stock. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the period. Brandes Investment Partners LP increased its position in Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after buying an additional 208,136 shares in the last quarter. Managed Asset Portfolios LLC raised its stake in Takeda Pharmaceutical by 1.3% during the 2nd quarter. Managed Asset Portfolios LLC now owns 1,488,843 shares of the company’s stock worth $23,018,000 after buying an additional 19,177 shares during the period. Bank of America Corp DE boosted its holdings in Takeda Pharmaceutical by 225.8% in the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after acquiring an additional 718,805 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in Takeda Pharmaceutical by 54.5% in the second quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock valued at $12,322,000 after acquiring an additional 280,992 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TAK shares. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Down 0.0%

Shares of NYSE:TAK opened at $16.16 on Wednesday. The business’s 50 day moving average is $15.02 and its 200 day moving average is $14.71. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $16.48. The stock has a market cap of $51.40 billion, a price-to-earnings ratio of 201.94 and a beta of 0.03. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, meeting the consensus estimate of $0.44. The business had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.